23 May 2013
Keywords: immupharma, lupus, drug, enters, ph, ii, london
Article | 17 July 2006
London, UK-headquartered drug discovery company ImmuPharma says that its developmental lupus treatment, IPP-201101, has entered Phase II
assessment. This follows ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 July 2006
24 July 2006
22 May 2013
© 2013 thepharmaletter.com